Compare FNWB & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | CRDL |
|---|---|---|
| Founded | 1923 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 97.3M |
| IPO Year | 2012 | 2017 |
| Metric | FNWB | CRDL |
|---|---|---|
| Price | $9.04 | $1.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $13.50 | $9.00 |
| AVG Volume (30 Days) | 24.2K | ★ 312.0K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $176,000.00 | N/A |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.05 | $0.77 |
| 52 Week High | $10.98 | $1.59 |
| Indicator | FNWB | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 28.63 | 55.89 |
| Support Level | $7.56 | $0.95 |
| Resistance Level | $9.50 | $1.10 |
| Average True Range (ATR) | 0.32 | 0.04 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 12.55 | 69.97 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.